Biocon · BIOCON
Depreciation and interest now absorb almost all of Biocon's operating profit
Operating profit held steady, but higher depreciation cut Biocon's pre-tax profit to ₹55 crore, which makes shipments that slipped into October count for more than their size.
4 min read Published on
Published by
Inve Content team
Biocon earned ₹55 crore before tax in the quarter to September 2026, against ₹171 crore a year earlier. Its operating profit, sales less operating costs before depreciation, interest and other income, hardly moved: ₹831 crore against ₹835 crore. The gap between those two lines is the story for a holder. The biosimilars, insulin and generics group has spent years building plants and buying product rights, and the cost of that capacity now sits beneath operating profit, where it takes almost all of what the business earns.
Three lines explain the fall in pre-tax profit from a year earlier. Depreciation and amortisation, the charge that spreads the cost of plants and acquired product rights over their working lives, rose by ₹91 crore. Interest fell after the company reduced its borrowings, and other income dropped. The saving on interest was real; it was simply outweighed by the new depreciation.
Extra depreciation outweighed the interest saved, while operating profit barely moved
₹ cr
- Operating profit -4
- Other income -53
- Lower interest ₹32 crore
- Higher depreciation -91
- Profit before tax -116
This is the bill for a programme the company described openly. Earlier this year management said its major phase of investment was substantially complete. The balance sheet shows the switch: capital work in progress, the cost of plants not yet in use, fell by about a third between the end of March and the end of September while fixed assets rose, which is what happens as lines go into service and start to be depreciated. The chief financial officer said depreciation also reflects product rights capitalised for new launches and the new Malaysia line, and that he did not expect a large further increase.
Put interest and depreciation together and they came to ₹804 crore last quarter, or 96.8% of operating profit, calculated from the filed results. Interest also rose from the quarter before, which the chief financial officer put down partly to currency and partly to money tied up in working capital, as the company builds inventory for launches in the second half. With charges this close to operating profit, almost every rupee that operating profit gains or loses now passes straight through to the pre-tax line.
Depreciation and interest have climbed to almost all of Biocon's operating profit
₹ cr
Operating profit
- ₹835 crore Sep 25
- ₹834 crore Dec 25
- ₹1,020 crore Mar 26
- ₹847 crore Jun 26
- ₹831 crore Sep 26
Interest plus depreciation
- ₹745 crore Sep 25
- ₹725 crore Dec 25
- ₹745 crore Mar 26
- ₹760 crore Jun 26
- ₹804 crore Sep 26
That sensitivity is why one disclosure carries more weight than its size suggests. Management said some biosimilar shipments, mostly insulin and antibody medicines, left in September but reached customers in October, delayed by logistics problems that included the geopolitical situation, so the revenue was booked in October. An analyst reading the company's presentation put the amount at about ₹135 crore, and the chief financial officer said "Yes, yes. That's true", but then gave the amount as roughly $20 million, about ₹180 crore at the exchange rate implied by the company's earlier statements. He said such spillovers normally run at about 1% and this one was larger.
Where the costs landed matters as much as the revenue. According to the chief financial officer, everything except shipping and freight was already charged in the quarter just ended, so the profit on those sales moves into the current quarter. If he is right, a sum of between about two and a half and three and a quarter times last quarter's pre-tax profit, less freight, is coming through in one go. On the same basis the biosimilars unit's EBITDA margin, its profit before depreciation, interest and tax as a share of revenue, would have been roughly 26–27% instead of 22.2%, calculated from the reported segment figures by adding the shipments to both revenue and EBITDA. That would put it back within the range management reiterated.
Add back the October shipments and the biosimilars margin returns to the mid-20s range guided
%
- Quarter before, reported 25.5%
- Last quarter, reported 22.2%
- Last quarter, adding ₹135 crore 25.75%
- Last quarter, adding $20 million 26.8%
The shipments do not explain the whole quarter. Sales grew 2.2% from a year earlier; with the delayed revenue added back, growth would have been roughly 5–6%, still well short of the 10.0% of the quarter before, calculated from the filed results. The explanation also rests on management's word until the next results show the money arriving, and on a size that is not settled, since the analyst's rupee figure and the chief financial officer's dollar figure do not match.
Further out, the company pointed to two dated sources of revenue. A Brazilian government partnership has awarded its biologics arm a ten-year contract worth $400 million in total, with supplies due to begin before the current financial year ends. A settlement with Genentech sets licensed launch dates for its pertuzumab biosimilar, a breast cancer medicine, in Europe and the UK from early next calendar year and in the US later. Those sales would arrive on top of a depreciation charge the chief financial officer does not expect to rise much further, so most of any gain in operating profit would now reach the pre-tax line.
The record: full financial tables
Financials
Income statement, last 8 quarters
| Quarter end | Sales | YoY | Operating profit | Op. margin | Other income | PBT | Net profit |
|---|---|---|---|---|---|---|---|
| Sept 2026 | 4,389 | +2.2% | 831 | 18.9% | 28 | 55 | 57 |
| Jun 2026 | 4,336 | +10.0% | 847 | 19.5% | 41 | 128 | 137 |
| Mar 2026 | 4,517 | +2.3% | 1,020 | 22.6% | −28 | 248 | 199 |
| Dec 2025 | 4,173 | +9.2% | 834 | 20.0% | −176 | −68 | −52 |
| Sept 2025 | 4,296 | +19.7% | 835 | 19.4% | 81 | 171 | 133 |
| Jun 2025 | 3,942 | +14.8% | 766 | 19.4% | 62 | 97 | 89 |
| Mar 2025 | 4,417 | +12.8% | 1,078 | 24.4% | 57 | 487 | 459 |
| Dec 2024 | 3,821 | −3.4% | 752 | 19.7% | 53 | 156 | 81 |
Balance sheet
| As of | Equity | Debt | Investments | Fixed assets | CWIP | Total assets |
|---|---|---|---|---|---|---|
| Sept 2026 | 34,843 | 15,698 | 1,324 | 39,689 | 4,568 | 65,280 |
| Mar 2026 | 34,031 | 15,434 | 1,779 | 36,486 | 6,987 | 63,409 |
| Sept 2025 | 26,803 | 16,536 | 2,333 | 37,262 | 4,651 | 62,760 |
| Mar 2025 | 21,644 | 18,362 | 1,127 | 31,963 | 8,508 | 58,540 |